Is Recursion Pharmaceuticals Stock a Buy?
Werte in diesem Artikel
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.But does that make the stock worth buying right now, given the considerable uncertainties surrounding the actual merit of its AI-heavy approach? Let's dive in and figure it out.For the uninitiated, Recursion wants to become the go-to provider of AI-based drug discovery and development services for the biopharmaceutical industry. It's also developing a handful of therapies for cancers and rare diseases with its in-house research and development (R&D) capabilities.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Recursion Pharmaceuticals, A
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Recursion Pharmaceuticals, A
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
Nachrichten zu Recursion Pharmaceuticals, Inc Registered Shs -A-
Analysen zu Recursion Pharmaceuticals, Inc Registered Shs -A-
Keine Analysen gefunden.